Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities

36Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a broad spectrum of malignancies. This new class of agents also challenges oncologists with a unique set of immune-based toxicities. Early recognition and precise management of these toxicities can result in better outcomes, with minimization of toxicity and harm to the patient. This article provides a comprehensive review of immune-based toxicities caused by immune checkpoint inhibitors, including recommendations for their investigation and guidelines for specific management.

Author supplied keywords

Cite

CITATION STYLE

APA

Roberts, K., Culleton, V., Lwin, Z., O’Byrne, K., & Hughes, B. G. M. (2017, August 1). Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia-Pacific Journal of Clinical Oncology. Blackwell Publishing Ltd. https://doi.org/10.1111/ajco.12698

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free